Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, 4-Week Randomised, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy

Trial Profile

A Phase II, 4-Week Randomised, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs GRC 17536 (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals Ltd
  • Most Recent Events

    • 26 Jan 2019 This trial has been completed in the United Kingdom as per the European Clinical Trials Database record.
    • 01 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Sep 2014 Interim results published in a Glenmark Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top